Similar to Aβ42, most studies have reported significantly higher levels of total tau, p-T181-tau, and p-S396-tau in NDEs of AD compared to pre-clinical AD/HC (Fiandaca et al., 2015; Abner et al., 2016; Goetzl et al., 2016b; Winston et al., 2016; Jia et al., 2019; Gu et al., 2020; Nam et al., 2020; Chi et al., 2022) and pre-clinical AD compared to HC (Goetzl et al., 2016b; Winston et al., 2016; Jia et al., 2019; Chi et al., 2022). This evidence concerns the gene MAPT and Alzheimer disease.